| Smell dysfunction: a biomarker for COVID‐19 ST Moein, SMR Hashemian, B Mansourafshar, A Khorram‐Tousi, ... International forum of allergy & rhinology 10 (8), 944-950, 2020 | 933 | 2020 |
| Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran AA Velayati, MR Masjedi, P Farnia, P Tabarsi, J Ghanavi, AH ZiaZarifi, ... Chest 136 (2), 420-425, 2009 | 903 | 2009 |
| Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients SD Ahuja, D Ashkin, M Avendano, R Banerjee, M Bauer, JN Bayona, ... Public Library of Science 9 (8), e1001300, 2012 | 741 | 2012 |
| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar, LF Anderson, ... The Lancet 392 (10150), 821-834, 2018 | 533 | 2018 |
| Diabetes mellitus and tuberculosis facts and controversies P Baghaei, M Marjani, P Javanmard, P Tabarsi, MR Masjedi Journal of Diabetes & Metabolic Disorders 12, 1-8, 2013 | 223 | 2013 |
| Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study H Abolghasemi, P Eshghi, AM Cheraghali, AAI Fooladi, FB Moghaddam, ... Transfusion and Apheresis Science 59 (5), 102875, 2020 | 214 | 2020 |
| Cancers related to immunodeficiencies: update and perspectives E Mortaz, P Tabarsi, D Mansouri, A Khosravi, J Garssen, A Velayati, ... Frontiers in immunology 7, 365, 2016 | 191 | 2016 |
| Interaction of pattern recognition receptors with Mycobacterium tuberculosis E Mortaz, IM Adcock, P Tabarsi, MR Masjedi, D Mansouri, AA Velayati, ... Journal of clinical immunology 35, 1-10, 2015 | 191 | 2015 |
| The immune response and immunopathology of COVID-19 E Mortaz, P Tabarsi, M Varahram, G Folkerts, IM Adcock Frontiers in immunology 11, 558378, 2020 | 189 | 2020 |
| ISG15 deficiency and increased viral resistance in humans but not mice SD Speer, Z Li, S Buta, B Payelle-Brogard, L Qian, F Vigant, E Rubino, ... Nature communications 7 (1), 11496, 2016 | 182 | 2016 |
| SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study H Poustchi, M Darvishian, Z Mohammadi, A Shayanrad, A Delavari, ... The Lancet Infectious Diseases 21 (4), 473-481, 2021 | 178 | 2021 |
| Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23 R Martínez-Barricarte, JG Markle, CS Ma, EK Deenick, N Ramírez-Alejo, ... Science immunology 3 (30), eaau6759, 2018 | 176 | 2018 |
| Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity S Baniasadi, P Eftekhari, P Tabarsi, F Fahimi, MR Raoufy, MR Masjedi, ... European journal of gastroenterology & hepatology 22 (10), 1235-1238, 2010 | 161 | 2010 |
| Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first-and second-line drugs: an … ML Bastos, H Hussain, K Weyer, L Garcia-Garcia, V Leimane, CC Leung, ... Clinical infectious diseases 59 (10), 1364-1374, 2014 | 159 | 2014 |
| COVID-19 and substance use disorders: Recommendations to a comprehensive healthcare response. an international society of addiction medicine practice and policy interest group … A Farhoudian, A Baldacchino, N Clark, G Gerra, H Ekhtiari, G Dom, ... Basic and Clinical Neuroscience 11 (2), 133, 2020 | 139 | 2020 |
| Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level AA Velayati, P Farnia, MR Masjedi, TA Ibrahim, P Tabarsi, RZ Haroun, ... European Respiratory Journal 34 (5), 1202-1203, 2009 | 131 | 2009 |
| Differences in Cell Wall Thickness between Resistant and Nonresistant Strains of Mycobacterium tuberculosis: Using Transmission Electron Microscopy AA Velayati, P Farnia, TA Ibrahim, RZ Haroun, HO Kuan, J Ghanavi, ... Chemotherapy 55 (5), 303-307, 2009 | 118 | 2009 |
| Anti-tuberculosis drug resistance and associated risk factors in a tertiary level TB center in Iran: a retrospective analysis MA Merza, P Farnia, P Tabarsi, M Khazampour, MR Masjedi, AA Velayati The Journal of Infection in Developing Countries 5 (07), 511-519, 2011 | 111 | 2011 |
| First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance M Shamaei, M Marjani, E Chitsaz, M Kazempour, M Esmaeili, P Farnia, ... International Journal of Infectious Diseases 13 (5), e236-e240, 2009 | 111 | 2009 |
| Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVID‐19 patients ST Moein, SMR Hashemian, P Tabarsi, RL Doty International forum of allergy & rhinology 10 (10), 1127-1135, 2020 | 108 | 2020 |
